Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.58 |
| ▸ | NAAA | Q02083 | 2/20 | 0.57 |
| ▸ | REN | P00797 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 1/20 | 0.54 |
| ▸ | RRM1 | P23921 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16994019 | 1.00 | DPP7 (0.58) | DPP7NAAARENHPGDTLR2 | |
| SCHEMBL8913994 | 0.99 | NAAA (0.59) | DPP7NAAARENHPGDTLR2 | |
| SCHEMBL8914221 | 0.99 | NAAA (0.59) | DPP7NAAARENHPGDTLR2 | |
| SCHEMBL17941645 | 0.99 | NAAA (0.59) | DPP7NAAARENHPGDTLR2 | |
| SCHEMBL3159222 | 0.99 | NAAA (0.59) | DPP7NAAARENHPGDTLR2 | |
| SCHEMBL12555472 | 0.99 | NAAA (0.59) | DPP7NAAARENHPGDTLR2 | |
| SCHEMBL17941646 | 0.99 | NAAA (0.59) | DPP7NAAARENHPGDTLR2 | |
| SCHEMBL8914559 | 0.99 | NAAA (0.59) | DPP7NAAARENHPGDTLR2 | |
| SCHEMBL29129460 | 0.99 | NAAA (0.59) | DPP7NAAARENHPGDTLR2 | |
| Hydrochloric Acid SCHEMBL31629095 | 0.97 | NAAA (0.58) | DPP7NAAARENHPGDTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255062-B2 | Fatty acid derivatives for oral administration endowed with high palatability | RHEA INNOVATIONS S.R.L. (IT) | 2016-02-09 | — | — | US | disclosed |
| EP-2268605-B1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2014-06-04 | — | — | EP | disclosed |
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | RHEA INNOVATIONS S.R.L. (IT) | 2011-04-28 | — | — | US | disclosed |
| EP-2268605-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PAIA- TABILITY | Berni Canani, Roberto (IT) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009130735-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | FABP2, FFAR2, VIP | DPP7 1207/4885NAAA 844/4885REN 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.